Bachem
Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.
Corporate information
- Company entity
- Bachem Holding AG
- Headquarters / principal office
- BubendorfSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 1971 ↗
- Ownership / capital status
- Publicly tradedPublicly traded (SIX; IPO in 1998) ↗
- Official corporate reference
- https://www.bachem.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2023-03-10 · Post-IPO follow-on offering · Approximately CHF 108.1 million (gross offering proceeds) ↗
Historical event verified in this review; subsequent financing is not ruled out.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.